Blog

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Photo taken from Howard McLeod/LinkedIn

May 1, 2024, 04:54

Howard McLeod: Preemptive DPYD Testing Program for patients planned for a systemic Fluoropyrimidine

Howard McLeod, Central Director, Founder and Advisor at Precision Medicine, shared on LinkedIn:

“The USA cancer community might be late to adopt Dihydropyrimidine dehydrogenase (DPYD) testing to avoid severe/fatal toxicity from commonly used chemotherapy, but the tide has finally changed. The recent Food and Drug Administration (FDA) package insert change is followed by very successful implementation at Dana-Farber Cancer Institute. With data from community centers, such as Atrium Health and St. Elizabeth Healthcare, there are no more excuses for rest of the field.”

Additional information
Source: Howard McLeod/LinkedIn

ASCO Atrium Health cancer Childhood Cancer Dana-Farber Cancer Institute dihydropyrimidine dehydrogenase DPYD testing FDA fluoropyrimidine Howard McLeod OncoDaily Oncology St. Elizabeth Healthcare

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers